Event

Connect with Quotient Sciences at the upcoming 14th Drug Delivery and Formulation Summit in Berlin from 31st May to 2nd June.

Schedule a meeting

News

Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

Oxilio and Quotient Sciences announced an update on the development of Oxilio’s OXL001 product, which uses Quotient Sciences’ Translational Pharmaceutics® platform.

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR

Partnership further expedites Ensysce’s development pipeline of PF614-MPAR, a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.

South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant Topline results expected Q3 2022

Clinical Trials Arena Interview with Stuart McDougall, VP of Bioanalytical Services on bioanalytical and pharmacokinetics (PK) strategies

Quotient's VP of Bioanalytical Services, Stuart McDougall was featured in an interview with Clinical Trials Area discussing the Bioanalytical and Pharmacokinetics (PK) strategies at Quotient, and how we reduce risk and delay within the drug development process.

Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences

Oxilio signed an exclusive global licensing agreement with TRx Biosciences on 20th October 2021 for the use of their platformtechnology to support the development of Oxilio’s formulation, OXL001. Oxilio has since progressed the product and nowsigned a significant service contract with Quotient Sciences, a drug development and manufacturing accelerator, to support the formulation development and preparation of clinical trials for OXL001.

Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics® Platform. The newly enhanced drug development platform will help empower innovators with the fastest[1] development timelines